Zymergen Acquires enEvolv
March 19, 2020
Zymergen has acquired enEvolv, a synthetic biology company that provides ultra-high throughput microbial screening and engineering. The acquisition brings enEvolv's biosensor-driven platform and team into Zymergen to accelerate discovery and commercialization of biologically-manufactured materials across electronics, consumer care, agriculture and other end markets.
- Buyers
- Zymergen
- Targets
- enEvolv
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eli Lilly Acquires Engage Biologics
May 23, 2026
Biotechnology
Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.
-
Emergence Acquires MedEvolve
November 11, 2025
Healthcare Services
Emergence, an enterprise backed by The Pritzker Organization, has acquired MedEvolve, an AI-powered revenue cycle automation and analytics provider. The acquisition combines MedEvolve’s Effective Intelligence platform with Emergence’s software expertise and long-term capital to accelerate AI-driven capabilities for healthcare revenue cycle management.
-
E Tech Group Acquires E-Volve Systems
March 2, 2023
Engineering Services
E Tech Group, a portfolio company of Falfurrias Capital Partners, has acquired E-Volve Systems, a provider of industrial automation, controls engineering and computer systems validation. The add-on expands E Tech Group's capabilities and presence in the life sciences, food & beverage, and consumer products markets; terms were not disclosed.
-
Ginkgo Bioworks to Acquire Zymergen
July 25, 2022
Biotechnology
Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
Ginkgo Bioworks Acquires Novogy's Microbial Engineering Platform
December 16, 2020
Biotechnology
Ginkgo Bioworks acquired the main assets of Novogy, Inc., absorbing Novogy's strain assets, IP portfolio, codebase and most of its technical team. The acquisition brings Novogy's expertise in lipid-producing oleaginous yeasts (notably Yarrowia lipolytica) into Ginkgo's cell‑programming platform to accelerate development of bio-based oils, chemicals and materials.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.